Development of methods detecting HLA-D region genes and their products regulating disease susceptibility
疾病易感性调控HLA-D区基因及其产物的检测方法开发
基本信息
- 批准号:60870017
- 负责人:
- 金额:$ 4.61万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Developmental Scientific Research
- 财政年份:1985
- 资助国家:日本
- 起止时间:1985 至 1986
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Gene products of HLA-D region (class <II> antigens) are involved in the development of a certain category of autoimmune diseases as an etiologic factor. DNA analysis suggested the presence of extra class <II> antigens in addition to four types of class <II> antigen system (DR, DRw52.53, DQ and DP). For the detection of these class <II> molecules, radioimmunoassay (RIA) instead of cytotoxic assay has been widely used. Since the use of radioisotopes, however, is rather restricted, we have been trying to establish non-radioisotopic assay systems for class <II> molecules in the hope that they can eventually be used in the field of clinical pathology.We have developed three kinds of enzyme immunoassay (EIA) using peroxidase-labeled anti-mouse Ig antibody or biotinylated anti-mouse Ig antibody and avidin-peroxidase.1. Solid phase EIA method in which solubilized class <II> molecules are attached to the well as target antigens: Various detergents and buffer systems for the attachment of target molecules have been tested. Deoxycholic acid as detergent and tris-HCl as buffer have yielded most reproducible results. The plates thus prepared can be used for three months if stored at -40゜C. It has also been confirmed that this method can be applied for immunochemical analysis of class <II> molecules.2. Cellular EIA method in which cells themselves are used as targets: Two versions of this method have been established using either Millititer SV plates (Millipore Corp.) or Immulon 600 flat-bottomed plates (Greiner). The former is convenient in that cells can be washed by aspiration from the bottom of the well, and the latter is advantageous because the plates can be stored for three months at 4゜C once cells are attached to the well. Furthermore, biotin-avidin system has been shown to be more sensitive than RIA in detecting class <II> antigens. We hope that these methods will be used in various fields of medical science.
HLA-D区域(<ii>抗原)的基因产物参与了特定类别的自身免疫性疾病作为病因学因素的发展。 DNA分析表明,除了四种类型的类抗原系统外,还存在额外的类抗原(DR,DRW52.53,DQ和DP)。为了检测这些类<ii>分子,已广泛使用了放射免疫测定(RIA)而不是细胞毒性测定。 Since the use of radioisotopes, however, is rather restricted, we have been trying to establish non-radioisotopic assay systems for class <II> molecules in the hope that they can sometimes be used in the field of clinical pathology.We have developed three kinds of enzyme immunoassay (EIA) using peroxidase-labeled anti-mouse Ig antibody or biotinylated anti-mouse Ig antibody and Avidin-过氧酶1。固相EIA方法,其中溶解的类<ii>分子与靶抗原相连:已测试了用于附着目标分子的各种确定剂和缓冲系统。确定的脱氧胆酸和TRIS-HCL作为缓冲液产生了最可重现的结果。这样准备的板如果存储在-40°C下,则可以使用三个月。还可以证实,该方法可以用于类分子的免疫化学分析2。细胞本身用作靶标的细胞EIA方法:已使用Millitter SV板(Millipore Corp.)或Immulon 600平底板(Greiner)建立了该方法的两个版本。前者很方便,因为可以通过从井的底部抽吸来洗涤细胞,而后者是有利的,因为一旦将细胞连接到井上,板就可以在4°C下在4°C下储存三个月。此外,在检测<ii>抗原中,已经证明生物素 - 阿维丁系统比RIA更敏感。我们希望这些方法将用于医学的各个领域。
项目成果
期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Murakami,M ed.MAizawa: HLA in Asia-Oceania 1986 (Hokkaido University Press,Sapporo Japan). 439-447 (1986)
Murakami,M ed.MAizawa:HLA in Asia-Oceania 1986(北海道大学出版社,日本札幌)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
山下幸紀: 日本産科婦人科学会雑志. 38. 17-22 (1986)
Yukinori Yamashita:日本妇产科学会杂志 38. 17-22 (1986)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Genshu Tate: "Analysis of HLA-class <II> antigen mRNAs on T lymphoblasts." Hokkaido J. Medical Science. 61. 249-256 (1986)
Genshu Tate:“T 淋巴细胞上 HLA 类 <II> 抗原 mRNA 的分析。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KATAGIRI Makoto其他文献
KATAGIRI Makoto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KATAGIRI Makoto', 18)}}的其他基金
Regulation mechanisms of the development of HLA-linked diseases by the complexes of HLA molecules and peptides.
HLA 分子和肽复合物对 HLA 相关疾病发展的调节机制。
- 批准号:
09470060 - 财政年份:1997
- 资助金额:
$ 4.61万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of HLA class II genes and functional roles of their products regulating disease susceptibility
HLA II类基因及其产物调节疾病易感性的功能作用分析
- 批准号:
02454165 - 财政年份:1990
- 资助金额:
$ 4.61万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似国自然基金
KIF17介导肿瘤细胞MHC-II胞膜定位促进乳腺癌抗原提呈及免疫应答的机制研究
- 批准号:82372781
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
MHC-II类分子抗原递呈在容量负荷致婴幼儿右心室成熟障碍中的作用和分子机制研究
- 批准号:82200309
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
MHC-II类分子抗原递呈在容量负荷致婴幼儿右心室成熟障碍中的作用和分子机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
改造抗原肽在抗肾小球基底膜病中的免疫治疗作用
- 批准号:81870482
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:面上项目
幽门螺杆菌感染与人类白细胞抗原II基因多态性的协同作用对Graves病易患性的影响及机制研究
- 批准号:81460154
- 批准年份:2014
- 资助金额:47.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Characterization of disulfide modified diabetogenic neoepitopes
二硫键修饰的糖尿病新表位的表征
- 批准号:
10720644 - 财政年份:2023
- 资助金额:
$ 4.61万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 4.61万 - 项目类别:
Decoding synovial CD4+ T cell antigen specificities in Rheumatoid Arthritis
解码类风湿性关节炎滑膜 CD4 T 细胞抗原特异性
- 批准号:
10569878 - 财政年份:2023
- 资助金额:
$ 4.61万 - 项目类别:
Machine learning optimized autoimmune therapeutics with a focus on Type 1 Diabetes
机器学习优化自身免疫疗法,重点关注 1 型糖尿病
- 批准号:
10697204 - 财政年份:2023
- 资助金额:
$ 4.61万 - 项目类别:
A Novel Melanoma Vaccine Based on a Shared Neoantigen and a Liquid Polymer Platform
基于共享新抗原和液体聚合物平台的新型黑色素瘤疫苗
- 批准号:
10697921 - 财政年份:2023
- 资助金额:
$ 4.61万 - 项目类别: